Connecting via Winsock to STN

```
Welcome to STN International! Enter x:x LOGINID:ssspta1613sxw
```

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

```
* * * * * * * *
                     Welcome to STN International
NEWS
                 Web Page URLs for STN Seminar Schedule - N. America
                 "Ask CAS" for self-help around the clock
NEWS
NEWS
         Feb 24
                 PCTGEN now available on STN
NEWS
         Feb 24
                 TEMA now available on STN
NEWS
         Feb 26
                 NTIS now allows simultaneous left and right truncation
     5
NEWS
      6
         Feb 26
                 PCTFULL now contains images
                 SDI PACKAGE for monthly delivery of multifile SDI results
NEWS
         Mar 04
NEWS
      8
         Mar 24
                 PATDPAFULL now available on STN
NEWS
     9
         Mar 24
                 Additional information for trade-named substances without
                 structures available in REGISTRY
                 Display formats in DGENE enhanced
NEWS 10
         Apr 11
NEWS 11
         Apr 14
                 MEDLINE Reload
NEWS 12
         Apr 17
                 Polymer searching in REGISTRY enhanced
NEWS 13
                 Indexing from 1947 to 1956 added to records in CA/CAPLUS
         Jun 13
NEWS 14
         Apr 21
                 New current-awareness alert (SDI) frequency in
                 WPIDS/WPINDEX/WPIX
NEWS 15
                 RDISCLOSURE now available on STN
         Apr 28
                 Pharmacokinetic information and systematic chemical names
NEWS 16
         May 05
                 added to PHAR
NEWS 17
         May 15
                 MEDLINE file segment of TOXCENTER reloaded
                 Supporter information for ENCOMPPAT and ENCOMPLIT updated
NEWS 18
         May 15
NEWS 19
         May 19
                 Simultaneous left and right truncation added to WSCA
NEWS 20
         May 19
                 RAPRA enhanced with new search field, simultaneous left and
                 right truncation
NEWS 21
         Jun 06
                 Simultaneous left and right truncation added to CBNB
NEWS 22
         Jun 06
                 PASCAL enhanced with additional data
                 2003 edition of the FSTA Thesaurus is now available
NEWS 23
         Jun 20
NEWS 24
         Jun 25
                 HSDB has been reloaded
NEWS 25
         Jul 16
                 Data from 1960-1976 added to RDISCLOSURE
                 Identification of STN records implemented
NEWS 26
         Jul 21
NEWS 27
         Jul 21
                 Polymer class term count added to REGISTRY
NEWS 28
         Jul 22
                 INPADOC: Basic index (/BI) enhanced; Simultaneous Left and
                 Right Truncation available
NEWS EXPRESS
              April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT
              MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP)
              AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
NEWS HOURS
              STN Operating Hours Plus Help Desk Availability
              General Internet Information
NEWS INTER
NEWS LOGIN
              Welcome Banner and News Items
NEWS PHONE
              Direct Dial and Telecommunication Network Access to STN
NEWS WWW
              CAS World Wide Web Site (general information)
```

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 13:38:46 ON 22 JUL 2003

=> fil reg
COST IN U.S. DOLLARS

SINCE FILE TOTAL
ENTRY SESSION
0.21 0.21

FULL ESTIMATED COST

FILE 'REGISTRY' ENTERED AT 13:38:54 ON 22 JUL 2003 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 21 JUL 2003 HIGHEST RN 552272-14-7 DICTIONARY FILE UPDATES: 21 JUL 2003 HIGHEST RN 552272-14-7

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 6, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details: http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=> Uploading 10000389c.str

L1 STRUCTURE UPLOADED

=> d L1 HAS NO ANSWERS L1 STR

G1 H,Ak G2 C,O,S,N

Structure attributes must be viewed using STN Express query preparation.

=> s 11 sss sam SAMPLE SEARCH INITIATED 13:39:11 FILE 'REGISTRY' SAMPLE SCREEN SEARCH COMPLETED - 14 TO ITERATE

100.0% PROCESSED 14 ITERATIONS

4 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 56 TO 504

PROJECTED ANSWERS: 4 TO 200

L2 4 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 13:39:16 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 254 TO ITERATE

100.0% PROCESSED 254 ITERATIONS

69 ANSWERS

SEARCH TIME: 00.00.01

L3 69 SEA SSS FUL L1

=> fil caplus

COST IN U.S. DOLLARS SINCE FILE TOTAL ENTRY SESSION 148.15 148.36

FILE 'CAPLUS' ENTERED AT 13:39:19 ON 22 JUL 2003 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 22 Jul 2003 VOL 139 ISS 4 FILE LAST UPDATED: 21 Jul 2003 (20030721/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 13 full

4 L3

=> d l4 1-4 ibib abs hitstr

ANSWER 1 OF 4 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER:

2003:15497 CAPLUS

DOCUMENT NUMBER:

TITLE:

138:78430

Pharmaceutical compositions containing heterocyclic

compounds as .alpha.1.beta.2 integrin-mediated adhesion inhibitors for treatment of inflammatory

INVENTOR(S):

Sircar, Ila; Furth, Paul; Teegarden, Bradley R.; Morningstar, Marshall; Smith, Nicholas; Griffith,

Ronald C.

PATENT ASSIGNEE(S):

SOURCE:

Tanabe Seiyaku Co., Ltd., Japan Jpn. Kokai Tokkyo Koho, 72 pp.

CODEN: JKXXAF

DOCUMENT TYPE:

LANGUAGE:

Patent Japanese

FAMILY ACC. NUM. COUNT:

PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE

JP 2003002834 A2 -----\_\_\_\_\_ JP 2002-117406 20020419 JP 2001-121235 A 20010419 20030108

PRIORITY APPLN. INFO.:

MARPAT 138:78430

OTHER SOURCE(S): GT

$$\begin{array}{c|c}
R & X \\
R & X \\
R & X \\
R & X \\
N - M & X
\end{array}$$

$$\begin{array}{cccc}
X & X \\
X & X \\
X & X \\
Y & X \\
Y & X \\
Y & X \\
Y & Y & Y$$

AB Title compns., useful for treatment of asthma, thrombosis, arteriosclerosis, osteoporosis, tumor, rheumatoid arthritis, etc., contain heterocyclic compds. I [A = :CZ1, :N; B = CR1R2, CH:CH, S, SO, SO2, O, NR3, NR3CO, etc.; K = CH2, CHOH, CO, CF2, M = bond, (CH2)p, CO, NH, W = :Q, CHR1C:Q, C:QCHR6; X, Y = H, halo, NO2, CN, C1-6 alkylthio, (un)substituted aryl, etc.; Z, Z1 = H, OH, halo, NO2, CF3, C1-6 alkoxycarbonyl, etc.; P, Q = O, S; R = (un)substituted (hetero)aryl; R1, R2 = H, halo, OR3, NR3R6, O2CNR32, N3, (un)substituted aryl, etc.; R1R2 may be linked to form O, etc.; R3 = H, (un)substituted C1-6 alkyl, (un)substituted (hetero)aryl, etc.; R6 = H, (un)substituted C1-6 alkyl; m = 0-3; n = 0-2, o, p = 1, 2] or their pharmacol. acceptable salts as active ingredients. Thus, (5R,7S)-5-[4-(trifluoromethoxy)benzyl]-3-(2,6-dichloro-4-pyridyl)-7-acetamido-1,3-diazabicyclo[3.3.0]octane-2,4-dione inhibited adhesion of Jurkat cell to ICAM-1 with IC50 value of 0.005 .mu.M.

IT 336812-89-6P 336812-90-9P 336812-91-0P 336812-92-1P 336812-93-2P 336816-67-2P 336816-69-4P 336816-73-0P 336816-77-4P 336816-81-0P 336817-14-2P 336817-20-0P 481704-12-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of heterocyclic compds. as .alpha.1.beta.2 integrin-mediated adhesion inhibitors for treatment of inflammatory diseases)

RN 336812-89-6 CAPLUS

Benzamide, N-[(6R,7aR)-7a-[(4-bromophenyl)methyl]-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

CN

RN

336812-90-9 CAPLUS Benzoic acid, 4-[[[(6R,7aR)-7a-[(4-bromophenyl)methyl]-2-(3,5-CNdichlorophenyl) hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6yl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN336812-91-0 CAPLUS

CNBenzamide, N-[(6R,7aR)-7a-[(4-bromophenyl)methyl]-2-(3,5dichlorophenyl) hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]-4-(dimethylamino) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.

336812-92-1 CAPLUS RN

Benzoic acid, 4-[[[(6R,7aR)-7a-[(4-bromophenyl)methyl]-2-(3,5-CNdichlorophenyl) hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6yl]amino]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

RN 336812-93-2 CAPLUS

CN Benzoic acid, 4-[[[(6R,7aR)-7a-[(4-bromophenyl)methyl]-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 336816-67-2 CAPLUS

CN Cyclopropanecarboxamide, N-[(6S,7aR)-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} C1 \\ \hline \\ N \\ \hline \\ S \\ R \\ \hline \\ \end{array}$$

RN 336816-69-4 CAPLUS

CN 3-Pyridinecarboxamide, N-[(6S,7aR)-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$F_3C$$

RN 336816-73-0 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[(6S,7aR)-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl]-5-oxo-, (2S)- (9CI) (CA INDEX NAME)

RN 336816-77-4 CAPLUS

CN 1-Piperazinebutanamide, N-[(6S,7aR)-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl]-4-methyl-.gamma.-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$\begin{array}{c|c} & & & & \\ & &$$

RN 336816-81-0 CAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(6S,7aR)-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c} & & & & \\ & & & \\ N & & & \\ N & & \\ N & & \\ S & & \\ R & & \\ \end{array}$$

RN 336817-14-2 CAPLUS

CN Morpholine, 4-[[(6R,7aR)-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl]carbonyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$F_3C$$

RN 336817-20-0 CAPLUS

$$\begin{array}{c|c} & & & & \\ & & \\ & & & \\ & & & \\ & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\$$

RN 481704-12-5 CAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-(3,5-dichlorophenyl)tetrahydro-6-[(6-methyl-3-pyridinyl)carbonyl]-7a-[[4-(trifluoromethoxy)phenyl]methyl]-, (6S,7aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Me 
$$F_3C$$

L4 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2002:428909 CAPLUS

DOCUMENT NUMBER: 137:6181

TITLE: Preparation of fused hydantoins as antiinflammatories.

INVENTOR(S): Iwanowicz, Edwin J.; Dhar, Murali T. G.; Launay, Michele; Potin, Dominique; Maillet, Magali Jeannine

Blandine; Nicolai, Eric Antoine

Blandine; Nicolai, Eric Ancoine

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA; CEREP SA SOURCE: PCT Int. Appl., 72 pp.

GOURCE: PCT Int. Appl., 72 pp. CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO. KIND DATE APPLICATION NO. DATE

GI

```
WO 2001-US45540 20011130
     WO 2002044181
                           Α1
                                 20020606
          W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
               CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GE, GH, GM,
               HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,
               UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
          RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
               CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
               BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
     AU 200227128200
                           A5
                                 20020611
                                                   AU 2002-27128
                                                                       20011130
                                                   US 2001-389
     US 2002143035
                           A1
                                 20021003
                                                                       20011130
PRIORITY APPLN. INFO.:
                                               US 2000-250486P
                                                                    P
                                                                       20001201
                                               US 2000-250653P
                                                                    Ρ
                                                                       20001201
                                               US 2001-272165P
                                                                    Ρ
                                                                       20010228
                                               WO 2001-US45540
                                                                   W
                                                                       20011130
OTHER SOURCE(S):
                             MARPAT 137:6181
```

Ι

433289-20-4P 433289-21-5P 433289-22-6P

433289-25-9P, (7AS,6S)-2-(3,5-dichlorophenyl)-6-(4-

$$\mathbb{R}^{4}$$
?

 $\mathbb{R}^{4}$ ?

Title compds. [I; L, K = O, S; M = N, CH; Y = CH, N; Z = H, (substituted) AΒ alkyl; T = N, CH, CR3; R1 = QX; X = (hetero)aryl; Q = bond, O, NR10, S, CO, CO2, NR10CO, NR10CO2, (substituted) alkylene, alkenylene, bivalent alkoxy, alkylthio, alkylamino, aminoalkyl, alkylsulfonyl, alkylsulfonamide, acyl, alkoxycarbonyl; R1R3 = fused carbocyclyl, heterocyclyl; R3 = halo, (substituted) alkyl, alkenyl, alkynyl, NO2, cyano, OR8, NR8R9, CO2R8, COR8, CONR8R9, NR8COR9, NR8CO2R9, OC(O)R8, OC(0)NR8R9, SR8, SOqR8a, NR8SO2Rg, SO2NR5Rq, aryl, heteroaryl, heterocyclo, cycloalkyl, O; 2 adjacent R3 form a (substituted) carbocyclic or heterocyclic fused ring; R4a, R4b = H, halo, (substituted) alkyl, alkenyl, alkynyl, NO2, cyano, OH, alkoxy, alkoxy, PhO, PhCH2O, CO2H, CHO, amino, CO2A, COA, alkylthio; A = alkyl; R8, R9 = H, (substituted) alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, aryl, heteroaryl, heterocyclyl; R8R9 = atoms to form a heterocyclic ring; R8a = (substituted) alkyl, cycloalkyl, aryl, heteroaryl, heterocyclo; R10 = H, (substituted) alkyl; Q1 = (CH2)s; Q2 = (CH2)r; n, s = 0, 1, 2; q = 1, 2, 3; r = 1, 2; with provisos], were prepd. as inhibitors of leukointegrin/ICAM assocd. conditions (no data). Thus, a mixt. of (7aS,6R)-2-(3,5-dichlorophenyl)-6hydroxytetrahydropyrrolo[1,2-c]imidazole-1,3-dione (prepn. given), Ph3P, and 4-bromophenol in THF at 0.degree. was treated with diisopropyl azodicarboxylate (DIAD) in THF followed by warming to room temp. overnight to give (7aS,6S)-2-(3,5-dichlorophenyl)-6-(4-bromophenoxy)tetrahydropyrrol o[1,2-c]imidazole-1,3-dione. 433289-16-8P, (7AS,6S)-2-(3,5-dichlorophenyl)-6-(4-IT bromophenoxy) tetrahydropyrrolo[1,2-c]imidazole-1,3-dione

bromobenzoyloxy)tetrahydropyrrolo[1,2-c]imidazole-1,3-dione 433289-27-1P, (6S,7AS)-6-(4-bromobenzyloxy)-2-(3,5dichlorophenyl) tetrahydropyrrolo[1,2-c]imidazole-1,3-dione 433289-28-2P 433289-29-3P 433289-30-6P 433289-31-7P 433289-32-8P 433289-33-9P 433289-34-0P 433289-38-4P 433289-39-5P 433289-40-8P 433289-41-9P 433289-42-0P 433289-43-1P 433289-44-2P RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (prepn. of fused hydantoins as antiinflammatories) RN433289-16-8 CAPLUS CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 6-(4-bromophenoxy)-2-(3,5dichlorophenyl)tetrahydro-, (6S,7aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 433289-20-4 CAPLUS

CN Benzonitrile, 4-[[[(6S,7aS)-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 433289-21-5 CAPLUS

CN Acetamide, N-[(4-cyanophenyl)methyl]-N-[(6S,7aS)-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]- (9CI) (CA INDEX NAME)

RN 433289-22-6 CAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-7a(5H)-acetic acid, 6-[(4-cyanophenyl)methoxy]-2-(3,5-dichlorophenyl)tetrahydro-1,3-dioxo-, methyl ester, (6R,7aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 433289-25-9 CAPLUS

CN Benzoic acid, 4-bromo-, (6S,7aS)-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 433289-27-1 CAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 6-[(4-bromophenyl)methoxy]-2-(3,5-dichlorophenyl)tetrahydro-, (6S,7aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 433289-28-2 CAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-(3,5-dichlorophenyl)tetrahydro-6-(phenylmethoxy)-, (6R,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 433289-29-3 CAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 6-[[(4-bromophenyl)methyl]thio]-2-(3,5-dichlorophenyl)tetrahydro-, (6S,7aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 433289-30-6 CAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 6-[(4-bromophenyl)methoxy]-2-(3,5-dichlorophenyl)tetrahydro-, (6R,7aR)- (9CI) (CA INDEX NAME)

RN 433289-31-7 CAPLUS

CN Benzonitrile, 4-[[[(6S,7aS)-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]oxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 433289-32-8 CAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 6-[(3-bromophenyl)methoxy]-2-(3,5-dichlorophenyl)tetrahydro-, (6S,7aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 433289-33-9 CAPLUS

CN [1,1'-Biphenyl]-2-carbonitrile, 4'-[[[(6S,7aS)-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]oxy]methyl]- (9CI) (CA INDEX NAME)

RN 433289-34-0 CAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 2-(3,5-dichlorophenyl)tetrahydro-6-(7-isoquinolinylmethoxy)-, (6S,7aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 433289-38-4 CAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 6-[[(4-bromophenyl)methyl]methylamino]-2-(3,5-dichlorophenyl)tetrahydro-, (6S,7aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 433289-39-5 CAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 6-[[2-(4-bromophenyl)ethyl]amino]-2-(3,5-dichlorophenyl)tetrahydro-, (6S,7aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 433289-40-8 CAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 6-[[3-(4-bromophenyl)propyl]amino]-2-(3,5-dichlorophenyl)tetrahydro-, (6S,7aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

Br 
$$(CH_2)_3$$
  $H$   $S$   $N$   $N$   $C1$   $C1$ 

RN 433289-41-9 CAPLUS

CN Benzonitrile, 4-[[[(6S,7aS)-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]ethylamino]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 433289-42-0 CAPLUS

CN Benzonitrile, 4-[[[(6S,7aS)-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]propylamino]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 433289-43-1 CAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 6-[(4-bromophenyl)methoxy]-2-(3,5-dichlorophenyl)tetrahydro-7a-methyl-, (6R,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 433289-44-2 CAPLUS

CN 1H-Pyrrolo[1,2-c]imidazole-1,3(2H)-dione, 6-[(4-bromophenyl)methoxy]-2-(3,5-dichlorophenyl)tetrahydro-7a-(hydroxymethyl)-, (6S,7aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

REFERENCE COUNT:

19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
ANSWER 3 OF 4 CAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER:
                            2002:90045 CAPLUS
DOCUMENT NUMBER:
                            136:151436
TITLE:
                            Preparation of combinatorial libraries of
                            N-arylsulfonyl-N-diazadioxobicyclooctyl amino acid
                            amides as drugs
                            Lu, Shao-Po; Hebert, R. Normand
INVENTOR (S):
PATENT ASSIGNEE(S):
                            Lion Bioscience A.-G., Germany
SOURCE:
                            PCT Int. Appl., 128 pp.
                            CODEN: PIXXD2
DOCUMENT TYPE:
                            Patent
LANGUAGE:
                            English
FAMILY ACC. NUM. COUNT:
PATENT INFORMATION:
     PATENT NO.
                       KIND DATE
                                               APPLICATION NO. DATE
      WO 2002008227
                       A2 20020131
                                              WO 2001-EP8322 20010718
          W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
              CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
          RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
              DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
              BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
      EP 1301512
                         A2 20030416
                                              EP 2001-960516 20010718
          R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
              IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
PRIORITY APPLN. INFO.:
                                            US 2000-621177
                                                               A 20000721
                                            WO 2001-EP8322
                                                               W 20010718
OTHER SOURCE(S):
                           MARPAT 136:151436
     RZN(SO2R1)CHR2CONH2 [I; R = (un) substituted Ph or CH2Ph; R1 = (un)
     2-methoxycarbonyl-3-thienyl, substituted Ph, etc.; R2 = amino acid side
     chain; Z = 1,3-diaza-2,4-dioxobicyclo[3.3.0]octane-3,6-diyl] were prepd.
     Data for antibacterial activity of I were given.
IT
     393876-35-2P 393876-37-4P 393876-39-6P
     393876-44-3P 393876-46-5P 393876-47-6P
     393876-54-5P 393876-55-6P 393876-56-7P
     393876-57-8P 393876-61-4P 393876-62-5P
     393876-65-8P 393876-67-0P 393876-68-1P
     393876-72-7P 393876-75-0P 393876-76-1P
     393876-79-4P 393876-80-7P 393876-81-8P
     393876-82-9P 393876-83-0P 393876-84-1P
     393876-85-2P 393876-89-6P 393876-90-9P
     393876-91-0P 393876-92-1P 393876-93-2P
     393876-94-3P 393876-95-4P 393876-96-5P
     393876-97-6P 393877-00-4P
     RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); THU
     (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study);
     PREP (Preparation); USES (Uses)
         (prepn. of combinatorial libraries of N-arylsulfonyl-N-
         diazadioxobicyclooctyl amino acid amides as drugs)
     393876-35-2 CAPLUS
RN
CN
     2-Thiophenecarboxylic acid, 3-[[[(1S)-2-amino-2-oxo-1-
     (phenylmethyl) ethyl] [(6S,7aS)-2-(3-fluorophenyl) hexahydro-1,3-dioxo-1H-
     pyrrolo[1,2-c]imidazol-6-yl]amino]sulfonyl]-, methyl ester (9CI)
```

INDEX NAME)

Absolute stereochemistry.

RN393876-37-4 CAPLUS

2-Thiophenecarboxylic acid, 3-[[[(1S)-2-amino-2-oxo-1-CN(phenylmethyl) ethyl] [(6S, 7aS) -2-(4-butoxyphenyl) hexahydro-1, 3-dioxo-1H-

pyrrolo[1,2-c]imidazol-6-yl]amino]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

393876-39-6 CAPLUS RN

2-Thiophenecarboxylic acid, 3-[[[(1S)-2-amino-1-[(4-methoxyphenyl)methyl]-CN2-oxoethyl] [(6S,7aS)-hexahydro-1,3-dioxo-2-phenyl-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 393876-44-3 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[[(1S)-2-amino-1-[(4-chlorophenyl)methyl]-2-oxoethyl][(6S,7aS)-2-(3,4-dimethylphenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 393876-46-5 CAPLUS

CN 1H-Imidazole-4-propanamide, .alpha.-[[(6S,7aS)-2-(4-butylphenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl][(3-fluorophenyl)sulfonyl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)

RN 393876-47-6 CAPLUS

CN Cyclohexanepropanamide, .alpha.-[[(3-fluorophenyl)sulfonyl][(6S,7aS)-hexahydro-2-[3-(methylthio)phenyl]-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 393876-54-5 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[[(1S)-2-amino-2-oxo-1-(phenylmethyl)ethyl][(6S,7aS)-hexahydro-2-(4-methylphenyl)-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 393876-55-6 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[[(1S)-2-amino-1-[(4-methoxyphenyl)methyl]-2-oxoethyl][(6S,7aS)-hexahydro-2-(3-methylphenyl)-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 393876-56-7 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[[(1S)-2-amino-1-[(4-methoxyphenyl)methyl]-2-oxoethyl][(6S,7aS)-2-(3-ethylphenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 393876-57-8 CAPLUS

CN 1H-Imidazole-4-propanamide, .alpha.-[[(4-bromophenyl)sulfonyl][(6S,7aS)-2-(2,5-dichlorophenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 393876-61-4 CAPLUS

CN Benzenepropanamide, .alpha.-[[(6S,7aS)-hexahydro-1,3-dioxo-2-(2,4,5-trimethylphenyl)-1H-pyrrolo[1,2-c]imidazol-6-yl][[3-(trifluoromethyl)phenyl]sulfonyl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)

RN 393876-62-5 CAPLUS

CN Cyclohexanepropanamide, .alpha.-[[(6S,7aS)-2-(2-ethylphenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl][(3-fluorophenyl)sulfonyl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 393876-65-8 CAPLUS

CN 1H-Imidazole-4-propanamide, .alpha.-[[(4-bromophenyl)sulfonyl][(6S,7aS)-2-(3-ethylphenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)

RN 393876-67-0 CAPLUS

CN 1H-Imidazole-4-propanamide, .alpha.-[[(6S,7aS)-2-(4-butoxyphenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl][(5-chloro-3-methylbenzo[b]thien-2-yl)sulfonyl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 393876-68-1 CAPLUS

CN Cyclohexanepropanamide, .alpha.-[[(6S,7aS)-2-(3-ethylphenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl][(3-fluorophenyl)sulfonyl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)

RN 393876-72-7 CAPLUS

CN Benzenepropanamide, 4-chloro-.alpha.-[[(4-chlorophenyl)sulfonyl][(6S,7aS)-2-(4-fluorophenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 393876-75-0 CAPLUS

CN Cyclohexanepropanamide, .alpha.-[[(4-bromophenyl)sulfonyl][(6S,7aS)-hexahydro-2-[3-(methylthio)phenyl]-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)

Br 
$$S$$
  $NH_2$   $O$   $S$   $S$   $N$   $N$   $S$   $S$   $S$ 

RN 393876-76-1 CAPLUS

CN 1H-Imidazole-4-propanamide, .alpha.-[[(6S,7aS)-2-(4-butylphenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl][(4-fluorophenyl)sulfonyl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 393876-79-4 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[[(1S)-2-amino-1-[(4-methoxyphenyl)methyl]-2-oxoethyl][(6S,7aS)-2-(2,4-dichlorophenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 393876-80-7 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[[(1S)-2-amino-2-oxo-1-(phenylmethyl)ethyl][(6S,7aS)-hexahydro-2-[3-(methylthio)phenyl]-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 393876-81-8 CAPLUS

CN Benzenepropanamide, .alpha.-[[(6S,7aS)-2-(3-fluorophenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl](2-thienylsulfonyl)amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)

RN 393876-82-9 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[[(1S)-2-amino-1-[(4-methoxyphenyl)methyl]-2-oxoethyl][(6S,7aS)-2-(2-fluorophenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 393876-83-0 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[[(1S)-2-amino-1-[(4-methoxyphenyl)methyl]-2-oxoethyl][(6S,7aS)-2-(3-chlorophenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 393876-84-1 CAPLUS

CN 1H-Imidazole-4-propanamide, .alpha.-[[(4-bromophenyl)sulfonyl][(6S,7aS)-2-(2,4-dichlorophenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]-, (.alpha.S)-(9CI) (CA INDEX NAME)

RN 393876-85-2 CAPLUS

CN 1H-Imidazole-4-propanamide, .alpha.-[[(6S,7aS)-2-(4-butylphenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl](2-thienylsulfonyl)amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 393876-89-6 CAPLUS

CN Cyclohexanepropanamide, .alpha.-[[(6S,7aS)-2-(3,5-dimethylphenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl][(3-fluorophenyl)sulfonyl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)

RN 393876-90-9 CAPLUS

CN Benzenepropanamide, .alpha.-[[(6S,7aS)-2-(5-fluoro-2-methylphenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl][[4-(trifluoromethyl)phenyl]sulfonyl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 393876-91-0 CAPLUS

CN Benzenepropanamide, .alpha.-[[(6S,7aS)-2-(2,4-dimethylphenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl][[4-(trifluoromethyl)phenyl]sulfonyl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)

RN 393876-92-1 CAPLUS

CN Cyclohexanepropanamide, .alpha.-[[(6S,7aS)-2-(2,5-dichlorophenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl][(3-fluorophenyl)sulfonyl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 393876-93-2 CAPLUS

CN Benzenepropanamide, .alpha.-[[(6S,7aS)-2-[4-(dimethylamino)phenyl]hexahydr o-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl][[4-(trifluoromethyl)phenyl]sulfonyl]amino]-, (.alpha.S)- (9CI) (CA INDEX

RN 393876-94-3 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[[(1S)-2-amino-1-[(4-methoxyphenyl)methyl]-2-oxoethyl][(6S,7aS)-hexahydro-2-[4-(1-methylethyl)phenyl]-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 393876-95-4 CAPLUS

CN 2-Thiophenecarboxylic acid, 3-[[[(1S)-2-amino-1-[(4-methoxyphenyl)methyl]-2-oxoethyl][(6S,7aS)-2-(2,6-difluorophenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)

RN 393876-96-5 CAPLUS

CN 1H-Imidazole-4-propanamide, .alpha.-[[(6S,7aS)-2-(4-butylphenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl][(3,4-difluorophenyl)sulfonyl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 393876-97-6 CAPLUS

CN 1H-Imidazole-4-propanamide, .alpha.-[[(4-bromophenyl)sulfonyl][(6S,7aS)-2-(4-butylphenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)

RN393877-00-4 CAPLUS

Cyclohexanepropanamide, .alpha.-[[(3-fluorophenyl)sulfonyl][(6S,7aS)-hexahydro-2-[2-methyl-6-(1-methylethyl)phenyl]-1,3-dioxo-1H-pyrrolo[1,2-CNc]imidazol-6-yl]amino]-, (.alpha.S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

CAPLUS COPYRIGHT 2003 ACS on STN ANSWER 4 OF 4

ACCESSION NUMBER: 2001:319894 CAPLUS DOCUMENT NUMBER:

134:326532

TITLE: Preparation of 3-(hetero)aryl-1,3-

> diazabicyclo[3.3.0]octane-2,4-diones and analogs as inhibitors of .alpha.1.beta.2 mediated cell adhesion

INVENTOR (S): Sircar, Ila; Furth, Paul; Teegarden, Bradley R.;

Morningstar, Marshall; Smith, Nicholas; Griffith,

Ronald C.

PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd., Japan

SOURCE: PCT Int. Appl., 195 pp.

CODEN: PIXXD2 DOCUMENT TYPE: Patent

LANGUAGE:

English 1

FAMILY ACC. NUM. COUNT: PATENT INFORMATION:

> PATENT NO. KIND DATE

APPLICATION NO.

```
_____
      WO 2001030781
                                   20010503
                           A2
                                                     WO 2000-US29273 20001019
      WO 2001030781
                            A3
                                   20011122
               AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
                SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
                YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
           RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
                DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
                CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
      BR 2000014651
                                   20020618
                            Α
                                                     BR 2000-14651
                                                                           20001019
      JP 2003512468
                            T2
                                   20030402
                                                     JP 2001-533134
                                                                           20001019
      EP 1307455
                                   20030507
                                                     EP 2000-976625
                            A2
                                                                           20001019
              AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
                IE, SI, LT, LV, FI, RO, MK, CY, AL
PRIORITY APPLN. INFO.:
                                                  US 1999-160629P P
                                                                           19991020
                                                  US 2000-209847P
                                                                     P
                                                                           20000607
                                                  WO 2000-US29273 W
                                                                           20001019
OTHER SOURCE(S):
                               MARPAT 134:326532
```

Title compds. (I) [wherein A = :CZ1 or :N; B = CH:CH, S, SO, SO2, O, or AB(un) substituted N or CH2; K = CH2, CHOH, CO, or CF2, M = a bond, (CH2)p, CO, or NH; W = CQ, CR6C(:Q), or C(:Q)CR6; X and Y = independently H, halo, NO2, CN, alkylthio, (halo)alkyl, alkoxy, acyl, or (un)substituted amino or (hetero)aryl; Z and Z1 = independently H, OH, halo, NO2, CF3, acyl, (un) substituted amino, carbamoyl, or alkoxy; P and Q = independently O or S; R = (un)substituted (hetero)aryl; R6 = H or (un)substituted alkyl; m = 0-3; n = 0-2; p and q = independently 1 or 2; or a pharmaceuticallyacceptable salt thereof] were prepd. as inhibitors of .alpha.1.beta.2 mediated cell adhesion. For example, 4-bromobenzyl bromide was added to N-(tert-butoxycarbonyl)proline Me ester in THF, the proline deprotected using TFA, 3,5-dichlorophenyl isocyanate added in the presence of DIEA in THF, and the dichlorophenylcarbamoyl deriv. cyclized using NaOEt in EtOH to afford II. In the Jurkat/ICAM-1 adhesion assay, I gave IC50 values from low nM to .mu.M. I are useful in the treatment of a variety of inflammatory diseases, including psoriasis, rheumatoid arthritis, inflammatory bowel diseases, systemic lupus erythematosus, atopic dermatitis, Sjogren's Syndrome, rejection after transplantation, and graft vs. host disease (no data).

IT 336812-89-6P 336812-90-9P 336812-91-0P

dichlorophenyl) hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl] - (9CI)

(CA INDEX NAME)
Absolute stereochemistry.

RN 336812-90-9 CAPLUS CN Benzoic acid, 4-[[[

Benzoic acid, 4-[[[(6R,7aR)-7a-[(4-bromophenyl)methyl]-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6-yl]amino]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 336812-91-0 CAPLUS

CNBenzamide, N-[(6R,7aR)-7a-[(4-bromophenyl)methyl]-2-(3,5dichlorophenyl) hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c] imidazol-6-yl]-4-(dimethylamino) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN336812-92-1 CAPLUS

Benzoic acid, 4-[[[(6R,7aR)-7a-[(4-bromophenyl)methyl]-2-(3,5-CNdichlorophenyl) hexahydro-1, 3-dioxo-1H-pyrrolo[1,2-c]imidazol-6yl]amino]carbonyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN

336812-93-2 CAPLUS Benzoic acid, 4-[[[(6R,7aR)-7a-[(4-bromophenyl)methyl]-2-(3,5-CN dichlorophenyl) hexahydro-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-6yl]amino]carbonyl] - (9CI) (CA INDEX NAME)

RN 336816-67-2 CAPLUS

CN Cyclopropanecarboxamide, N-[(6S,7aR)-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$\begin{array}{c|c} & & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & & \\ & & \\ & & & \\ & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & & \\ & &$$

RN 336816-69-4 CAPLUS

CN 3-Pyridinecarboxamide, N-[(6S,7aR)-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c}
 & C1 \\
 & N \\
 & N \\
 & R \\
 & O \\
 & C1 \\$$

RN 336816-71-8 CAPLUS

CN 3-Pyridinecarboxamide, N-[(6S,7aR)-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Me 
$$N$$
  $S$   $N$   $O$   $C1$   $C1$ 

RN 336816-73-0 CAPLUS

CN 2-Pyrrolidinecarboxamide, N-[(6S,7aR)-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl]-5-oxo-, (2S)- (9CI) (CA INDEX NAME)

RN 336816-77-4 CAPLUS

CN 1-Piperazinebutanamide, N-[(6S,7aR)-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl]-4-methyl-.gamma.-oxo-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$\begin{array}{c|c} & & & & \\ & &$$

RN 336816-81-0 CAPLUS

CN 1-Pyrrolidinecarboxamide, N-[(6S,7aR)-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl]- (9CI) (CA INDEX NAME)

$$\begin{array}{c|c}
 & C1 \\
 & N \\
 & N \\
 & N \\
 & N \\
 & C1 \\$$

RN 336817-14-2 CAPLUS

CN Morpholine, 4-[[(6R,7aR)-2-(3,5-dichlorophenyl)hexahydro-1,3-dioxo-7a-[[4-(trifluoromethoxy)phenyl]methyl]-1H-pyrrolo[1,2-c]imidazol-6-yl]carbonyl]-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

$$F_3C$$

RN 336817-20-0 CAPLUS

Page 45